Hepatitis C virus: Virology, diagnosis and treatment
Open Access
- 1 January 2015
- journal article
- review article
- Published by Baishideng Publishing Group Inc. in World Journal of Hepatology
- Vol. 7 (10), 1377-89
- https://doi.org/10.4254/wjh.v7.i10.1377
Abstract
More than twenty years of study has provided a better understanding of hepatitis C virus (HCV) life cycle, including the general properties of viral RNA and proteins. This effort facilitates the development of sensitive diagnostic tools and effective antiviral treatments. At present, serologic screening test is recommended to perform on individuals in the high risk groups and nucleic acid tests are recommended to confirm the active HCV infections. Quantization and genotyping of HCV RNAs are important to determine the optimal duration of anti-viral therapy and predict the likelihood of response. In the early 2000s, pegylated interferon plus ribavirin became the standard anti-HCV treatment. However, this therapy is not ideal. To 2014, boceprevir, telaprevir, simeprevir, sofosbuvir and Harvoni are approved by Food and Drug Administration for the treat of HCV infections. It is likely that the new all-oral, interferon-free, pan-genotyping anti-HCV therapy will be available within the next few years. Majority of HCV infections will be cured by these anti-viral treatments. However, not all patients are expected to be cured due to viral resistance and the high cost of antiviral treatments. Thus, an efficient prophylactic vaccine will be the next challenge in the fight against HCV infection.Keywords
This publication has 112 references indexed in Scilit:
- HCV E1E2‐MF59 vaccine in chronic hepatitis C patients treated with PEG‐IFNα2a and Ribavirin: a randomized controlled trialJournal of Viral Hepatitis, 2013
- A Hepatitis C Virus (HCV) Vaccine Comprising Envelope Glycoproteins gpE1/gpE2 Derived from a Single Isolate Elicits Broad Cross-Genotype Neutralizing Antibodies in HumansPLOS ONE, 2013
- Host Genetic Variants in the Pathogenesis of Hepatitis CViruses, 2012
- Performance of the Abbott RealTime HCV Genotype II RUO AssayJournal of Clinical Microbiology, 2012
- Hepatitis C Virus (HCV) Genotype 1 Subtype Identification in New HCV Drug Development and Future Clinical PracticePLOS ONE, 2009
- Telaprevir with Peginterferon and Ribavirin for Chronic HCV Genotype 1 InfectionThe New England Journal of Medicine, 2009
- The Cobas AmpliPrep-Cobas TaqMan real-time polymerase chain reaction assay fails to detect hepatitis C virus RNA in highly viremic genotype 4 clinical samplesJournal of Hepatology, 2008
- Evaluation of Versant Hepatitis C Virus Genotype Assay (LiPA) 2.0Journal of Clinical Microbiology, 2008
- Use of Sequence Analysis of the NS5B Region for Routine Genotyping of Hepatitis C Virus with Reference to C/E1 and 5′ Untranslated Region SequencesJournal of Clinical Microbiology, 2007
- Structural biology of hepatitis C virusJournal of Hepatology, 2004